Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
/ 26 items
#XY Analyst Up/Down↓
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Wall Street Backs Achieve Life Sciences: Cytisinicline Labeled 'Best-in-Class' Smoking Cessation Drug
Achieve Life Sciences gets Buy rating as its quit-smoking drug cytisinicline shows strong results; FDA decision due June 2026.
Cantor Fitzgerald Calls Candel Therapeutics Deeply Undervalued – Overweight Rating Initiated
Cantor is very bullish on CADL, sees big undervaluation and CAN-2409 as a major drug with huge growth potential.
Barclays Turns Bearish on Janux: Lead Program JANX007 Loses Confidence
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
Barclays Upgrades Celldex to Overweight, Raises Price Target to $45
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.